The stock of Second Sight Medical Products Inc (NASDAQ:EYES) closed at $1.94 losing 3.48% in yesterday’s trading session. Second Sight has today made the announcement regarding its market entry into Iran. The most recent in its efforts to developing working solutions for patients around the globe was the implantation of two patients with Argus® II Retinal Prosthesis System. Arshia Gostar Darman was the one that facilitated the implant and it exuded confidence in the project outlining that it was about enhancing lives.
The Chief Executive Officer of Second Sight, Will McGuire, opined, “These first implants in Iran are part of our strategy to selectively target and partner with leading eye centers and distribution partners around the world in order to increase the availability of the Argus II to individuals with Retinitis Pigmentosa. The adoption of Argus II by a growing number of centers globally is a testament to the increasing acceptance of our technology.”
Argus II works on a rather sophisticated mechanism. It works on the principle of converting the various images captured by the miniature video camera. Patients need to familiarize themselves with the visual patterns in an effort to regain what they apparently think of as the regaining of visual function. The Argus II will go down records as the first artificial retina to have obtained commercial approval. Patients can access it in approved centers in France, Canada, Italy, Germany, Saudi Arabia, Russia, Turkey, Spain and South Korea.
Second Sight in a recent statement outlined that it took the matter of healthcare with utmost importance. That is the reason why it has always grasped every opportunity that comes it way to develop working solutions for patients around the globe. However, it attests to the fact that its activities are not smooth all along the way considering that at times it is compelled to move past challenges.
It looks at its most recent move with great pride and exudes confidence that the future looks bright. It has outlined that it will be mobilizing it resources to ensure that it gains a competitive edge over rivals.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: